Immunology Market (By Drug Class: Monoclonal Antibodies, Fusion Proteins, Immunosuppressants, others; By Disease Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis Of Organ Rejection; By Distribution Channel: Hospital Pharmacie, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

The global immunology market size reached USD 98.22 billion in 2023 and is estimated to hit around USD 263.22 billion by 2033 with a CAGR of 10.36% from 2024 to 2033. As the world's population ages, illnesses linked to the immune system and aging-related diseases are becoming more common, driving the growth of the market.

Key Takeaway

• North America held the largest share of 53% in 2023.
• Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
• By drug class, the monoclonal antibodies segment held the largest share of the market.
• By disease indication, the rheumatoid arthritis segment held the largest share of the market.
• By distribution channel, the hospital pharmacies segment held the largest share of the market.

Immunology Market in the U.S. 2024 to 2033

The U.S. immunology market size was valued at USD 39.04 billion in 2023 and is anticipated to reach around USD 104.63 billion by 2033, poised to grow at a CAGR of 10.40% from 2024 to 2033.

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

North America held the largest market share of 53% in 2023. In North America, the prevalence of autoimmune disorders like psoriasis, Crohn's disease, and rheumatoid arthritis has been rising significantly. The need for immunology therapies and drugs is increasing due to this development. Nowadays, biological medications are a vital component of immunology care. These medications, made from living things, treat autoimmune illnesses by focusing on particular immune system components. Effective therapy choices for patients who do not respond well to conventional medications have been successfully provided by biologics. Companies such as AbbVie, Johnson & Johnson, Amgen, and Pfizer are a few of the prominent participants in the immunology market in North America that have significant stakes in the form of research and development of cutting-edge immunology medicines.

Asia Pacific is observed to witness the fastest rate of expansion during the forecast period. In Asia Pacific, the frequency of immune-related conditions such as allergies, psoriasis, inflammatory bowel disease, and rheumatoid arthritis is rising. This growth fuels the need for immunology treatments, diagnostics, and medications. Spending on healthcare has increased in nations like China, India, Japan, and South Korea due to their economies growing. Consequently, the immunology market is expanding as more funds are allotted to diagnosing and treating immune-related illnesses. The governments of many Asia Pacific nations are concentrating on enhancing the availability of healthcare services, developing immunological research and development, and enhancing the infrastructure supporting healthcare. For instance, the immunology market is growing due to efforts to promote biosimilars and lower healthcare expenditures.

Immunology Market Overview

The area of the pharmaceutical and healthcare industries that is dedicated to creating, manufacturing, and marketing goods for the diagnosis, treatment, and management of immune-related illnesses and ailments is known as the immunology market. This covers a range of medications, treatments, diagnostics, and research instruments intended to identify, manage, or prevent immune-mediated illnesses, including allergies, cancer immunotherapy, autoimmune diseases, and infectious diseases. These medications and treatments were created using biotechnological techniques, and they frequently target particular immune system components to alter their activity. Vaccines, immunomodulators, and monoclonal antibodies are a few examples.

Tests and assays used in immunology diagnostics evaluate immune system performance, find antibodies, antigens, or other immunological markers that may indicate a disease, and track therapy outcomes. ELISA assays, flow cytometry, and PCR-based diagnostics are a few examples. This includes continuous research into the underlying mechanisms of immune-related disorders, the development of novel immunological therapeutics, and the identification of possible targets for intervention. Immunological therapies, which aim to modulate or harness the immune system to treat various diseases, include small molecules, biologics, gene therapies, and cell-based therapies, among many more modalities, which are some of the several services produced by the immunology market.

Growth Factors

• Immunological therapy is becoming more and more popular as autoimmune disorders, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, become more common driving the growth of the immunology market.
• Immunological illnesses now have more therapeutic options thanks to technological developments in immunotherapy, such as immune checkpoint inhibitors, monoclonal antibodies, and cell-based therapies like CAR-T cell therapy. These improvements enhance both the market and patient results.
• Immunotherapy has become a viable treatment option for cancer, especially for melanoma, lung cancer, and several hematological malignancies. In oncology applications, the immunology market is anticipated to increase as research continues to identify new targets and therapeutic approaches.
• Globally, and especially in developed economies, rising healthcare spending encourages the use of cutting-edge immunological treatments. The willingness of public and private payers to reimburse these treatments is growing, propelling the expansion of the immunology market.
• As the immune system ages, the senior population is increasingly vulnerable to immunological illnesses. The aging of the world's population is creating a larger pool of patients needing immunological treatments, driving the growth of the immunology market.
• Drug development and immunology research are significant investment areas for academic research institutes, biotechnology corporations, and pharmaceutical companies. By identifying novel targets and creating cutting-edge treatments, this investment promotes the expansion of the immunology market.

Immunology Market Scope

Immunology Market Dynamics

Driver: Increasing investment in research and development

Novel immunological approaches are desperately needed in light of the ongoing rise of infectious illnesses such as COVID-19 and the danger of antibiotic resistance. To effectively address these risks, more money can be invested in research and development (R&D) to produce vaccinations, medicines, and diagnostic tools. The trend towards personalized medicine where therapies are customized for specific patients based on their immunological response, genetic composition, and other variables is being driven by advancements in immunology. Increased funding for research and development (R&D) can spur the creation of cutting-edge platforms and technologies that help scientists better understand the immune system and create novel treatments.

Restraint: Resistance and relapse

Cancer cells can create defenses against the immune system's recognition and assault. For instance, they might suppress the expression of chemicals that immunotherapies are intended to target. Immunosuppressive substances may be present in the tumor microenvironment, reducing immunotherapy's efficacy. Over time, cancer cells may develop additional mutations that make them resistant to the original treatment. By focusing on several routes, resistance can be overcome by combining several immunotherapies or immunotherapy with other forms of treatment, such as chemotherapy or targeted therapy. Research into novel immunotherapeutic drugs and treatment techniques must continue to overcome resistance and enhance long-term patient outcomes.

Opportunity: Immuno-oncology combinations

Oncological research and studies create several opportunities in the immunology market. Checkpoint inhibitors have been extensively researched with other immunotherapies, targeted treatments, chemotherapy, and radiation therapy. Examples of these combinations include PD-1/PD-L1 inhibitors and CTLA-4 inhibitors. In some cancer cases, combining immunotherapy with targeted therapies—like tyrosine kinase inhibitors (TKIs) or monoclonal antibodies that target particular signaling pathways—has shown potential. Immunotherapy can be more successful when it is used with radiation and chemotherapy to modify the immune system. Immunotherapy combinations with chemotherapy or radiation therapy are being investigated for various cancer types to increase response rates and overall survival. Another tactic to improve anti-tumor immune responses is to combine several immunotherapies, such as adoptive cell therapy or checkpoint inhibitors, with cytokines.

Drug Class Insights

The monoclonal antibodies segment held the largest share in the immunology market. An antibody known as a monoclonal antibody (mAb) is produced by immune cells, all clones of the same parent cell. These antibodies are highly specific to a specific antigen, a microbe, virus, or cancer cell. Monoclonal antibodies are widely used in medicine for therapy, diagnosis, and research. They are valuable tools for treating a wide range of illnesses, such as cancer, autoimmune disorders, and infectious diseases, since they may be designed to target specific molecules involved in diseases. Monoclonal antibodies have entirely transformed the therapy landscape for diseases like cancer, autoimmune diseases, inflammatory disorders, and infectious diseases.

Globally, the prevalence of conditions like psoriasis, inflammatory bowel illnesses, and rheumatoid arthritis is increasing, which has created a sizable market for monoclonal antibody therapy intended to reduce symptoms and enhance patients' quality of life. Pharmaceutical companies are investing in research and development to build a strong pipeline of possible treatments to find and develop innovative monoclonal antibody-based therapeutics for various immunological illnesses. Compared to conventional systemic medications, monoclonal antibodies provide tailored therapeutic techniques that selectively affect particular immune system components or disease pathways, resulting in more accurate and effective treatments with fewer side effects.

Disease Indication Insights

The rheumatoid arthritis segment held the largest share of the immunology market in 2023. Rheumatoid arthritis (RA) is a chronic autoimmune illness primarily affecting the joints. If treatment is not received, RA can cause discomfort, inflammation, joint destruction, and deformity. Since RA necessitates long-term management and treatment to control symptoms and stop disease progression, it represents a significant market share in the immunology sector.

The way rheumatoid arthritis is treated has changed dramatically because of biological treatments. These medications specifically target immune system elements contributing to inflammation, including B cells, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). In the treatment of RA, biologics such as TNF inhibitors (adalimumab, etanercept), IL-6 inhibitors (tocilizumab), and B cell-targeting medications (rituximab) are frequently utilized.

Methotrexate and other traditional DMARDs continue to be mainstays in treating rheumatoid arthritis. These medications reduce the aberrant immune response that causes inflammation and damage to joints. For increased efficacy, they are frequently used in conjunction with biologic therapy. New treatment medicines for rheumatoid arthritis are driving further changes in the immunology sector. Tofacitinib and baricitinib are examples of janus kinase (JAK) inhibitors, a more recent class of drugs that target intracellular signaling pathways implicated in inflammation. Individualized medicine methods are becoming increasingly important as knowledge about the genetic and molecular causes of rheumatoid arthritis advances.

Distribution Channel Insights

In 2023, the hospital pharmacies segment held the largest share in the immunology market, by distribution channel. Hospital pharmacies provide various immunology-related drugs, such as corticosteroids, immunosuppressants, monoclonal antibodies, and biologics. Healthcare professionals prescribe these drugs to treat various immune illnesses, including multiple sclerosis, psoriasis, inflammatory bowel disease, and rheumatoid arthritis. Hospital pharmacy employees and pharmacists must educate patients about their prescription drugs. Patients must comprehend the correct administration of immunological disorders, possible adverse effects, and the significance of adhering to treatment regimens. Hospital pharmacists counsel patients to make sure they take their drugs as prescribed.

Hospital pharmacies are in charge of keeping track of supplies and guaranteeing that immunological drugs are available. They collaborate closely with medical professionals to track how patients respond to treatment and modify drug schedules as necessary. In order to guarantee that immunosuppressive therapies are used appropriately and safely, pharmacists may also perform drug usage reviews. Pharmacies in hospitals frequently take part in clinical studies for novel immunological drugs. They might work with academic institutions and pharmaceutical businesses to make testing and assessment of new treatments easier. This research involvement facilitates the improvement of immunology therapy choices.

Recent Developments

• In July 2023, A biosimilar to AbbVie's Humira (adalimumab), Sandoz, a Novartis business, announced the U.S. launch of its citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-day). All indications, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa that are no longer covered by the reference medicine regulatory exclusivity are approved for treatment with Hyrimoz.
• In June 2022, OLUMIANT, produced by Eli Lilly and Company, received U.S. FDA approval as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), an autoimmune disorder.

Immunology Market Companies

• AbbVie Inc.
• Janssen Global Services, LLC (Johnson & Johnson)
• Novartis AG.
• ALLERGAN.
• Amgen Inc.
• Other Prominent Players.
• Merck Sharp & Dohme Corp.
• Bristol-Myers Squibb Company.

Segments Covered in the Report

By Drug Class

• Monoclonal Antibodies
• Fusion Proteins
• Immunosuppressants
• Others

By Disease Indication

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Plaque Psoriasis
• Ankylosing Spondylitis
• Inflammatory Bowel Disease
• Prophylaxis Of Organ Rejection

By Distribution Channel

• Hospital Pharmacie
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa